114 Recruiting Trials

Clinical Trials
for Cancer in New Hampshire

114 clinical trials for Cancer are currently recruiting participants at study sites in New Hampshire. Study-related care is provided at no cost.

114
Recruiting trials
44
Study sites
13
Cities
33
Industry-sponsored
42
Phase 2
49
Phase 3

Cancer clinical trials in New Hampshire: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In New Hampshire, recruiting cancer studies are concentrated in Lebanon, Manchester, Concord and Londonderry, with sites in 9 other cities. 33 of the 114 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 114 recruiting Cancer trials in New Hampshire

Pan Tumor Rollover Study
PHASE2 Huntsville, Alabama +4 sites NCT03899155
This trial is looking for patients with cancer who have had a good response to previous treatments. Participants will continue receiving nivolumab alone or in combination with other cancer therapies to study long-term safety.
Recruiting
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
PHASE2 Lebanon, New Hampshire NCT05405413
This trial is looking for adults with cancer to see how genetic testing can help guide their treatment. Participants will have their tumors tested for specific genetic changes and then receive recommendations from a team of experts.
Recruiting
Immune Profiling for Cancer Immunotherapy Response
N/A Lebanon, New Hampshire NCT06116032
This trial is looking for cancer patients who are receiving or will receive FDA-approved immunotherapy treatment. It involves assessing how the immune system's response may predict how well the treatment works.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
PHASE3 Tucson, Arizona +4 sites NCT06989112
This trial is looking for adults with a specific type of endometrial cancer. Participants will receive either a combination of two new treatments or a standard chemotherapy and immunotherapy to see how well they work.
Recruiting
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
PHASE3 Chandler, Arizona +4 sites NCT06377852
This trial is looking for older patients with metastatic breast cancer to test different dosing strategies for two medications. Participants will help researchers understand how well these strategies work and which might be better tolerated.
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
PHASE3 Mobile, Alabama +4 sites NCT07228832
This trial is looking for patients with metastatic colorectal cancer who have not received any previous treatment. Participants will receive either Ivonescimab or Bevacizumab combined with chemotherapy as their first treatment.
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
PHASE2 Springdale, Arkansas +4 sites NCT07155187
This trial is looking for adults with advanced lung cancer that has specific genetic mutations. Participants will receive either an experimental drug alone or in combination with another medication, while being closely monitored at regular visits.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
PHASE2 Anchorage, Alaska +4 sites NCT07063745
This trial is looking for people with advanced lung cancer who have a specific genetic change. Participants will receive either a combination of Navlimetostat, pembrolizumab, and chemotherapy or a placebo with the same treatments.
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3 Hot Springs, Arkansas +4 sites NCT07085767
This trial is looking for adults with advanced breast cancer that hasn’t been treated before. Participants will receive palazestrant with ribociclib or letrozole with ribociclib to see which treatment works better.
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
PHASE3 Tucson, Arizona +4 sites NCT07409272
This trial is looking for people with pancreatic cancer that has spread and a specific gene mutation. Participants will receive a medication called setidegrasib along with standard chemotherapy to see if it helps improve their treatment outcomes.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
PHASE3 Phoenix, Arizona +4 sites NCT06072612
This trial is looking for adults with advanced or locally recurrent breast cancer who have run out of treatment options. Participants will receive treatment with the Bria-IMT regimen and a checkpoint inhibitor to see how well it works compared to other standard treatments.
Recruiting
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
PHASE3 Loma Linda, California +4 sites NCT03257033
This trial is looking for adults with locally advanced pancreatic cancer that cannot be surgically removed. Participants will receive either intra-arterial gemcitabine or intravenous gemcitabine combined with nab-paclitaxel after their initial treatment.
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
PHASE3 Phoenix, Arizona +4 sites NCT05899608
This trial is looking for adults with stage IV non-small cell lung cancer who have not received any prior treatments. Participants will receive either Ivonescimab combined with chemotherapy or pembrolizumab combined with chemotherapy.
Recruiting

Where the Cancer studies are in New Hampshire

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon40 trials
  • Dartmouth-Hitchcock Medical Center, Lebanon20 trials
  • Solinsky Center for Cancer Care, Manchester19 trials
  • New Hampshire Oncology Hematology PA-Concord, Concord17 trials
  • Dartmouth Hitchcock Medical Center, Lebanon12 trials
  • The Dana-Farber Cancer Institute at Londonderry, Londonderry5 trials

Counts are recruiting studies listing at least one site in New Hampshire, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in New Hampshire: common questions

How many Cancer clinical trials are recruiting in New Hampshire?
TrialFinder currently lists 114 recruiting Cancer clinical trials with study sites in New Hampshire. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in New Hampshire?
Study sites for the Cancer trials listed on this page include Lebanon. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in New Hampshire?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in New Hampshire also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in New Hampshire?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in New Hampshire.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →